Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

NCT00502060 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Tumor

Interventions

DRUG: AZD2171
DRUG: ZD1839

Sponsor

AstraZeneca